129 related articles for article (PubMed ID: 16105968)
1. Hemostatic factors and estrogen during the menopausal transition.
Sowers MR; Matthews KA; Jannausch M; Randolph JF; McConnell D; Sutton-Tyrrell K; Little R; Lasley B; Pasternak R
J Clin Endocrinol Metab; 2005 Nov; 90(11):5942-8. PubMed ID: 16105968
[TBL] [Abstract][Full Text] [Related]
2. Insulin resistance, hemostatic factors, and hormone interactions in pre- and perimenopausal women: SWAN.
Sowers M; Derby C; Jannausch ML; Torrens JI; Pasternak R
J Clin Endocrinol Metab; 2003 Oct; 88(10):4904-10. PubMed ID: 14557472
[TBL] [Abstract][Full Text] [Related]
3. Menopause, complement, and hemostatic markers in women at midlife: the Study of Women's Health Across the Nation.
El Khoudary SR; Shields KJ; Chen HY; Matthews KA
Atherosclerosis; 2013 Nov; 231(1):54-8. PubMed ID: 24125410
[TBL] [Abstract][Full Text] [Related]
4. Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease.
Lindoff C; Peterson F; Lecander I; Martinsson G; Astedt B
Maturitas; 1996 May; 24(1-2):43-50. PubMed ID: 8794433
[TBL] [Abstract][Full Text] [Related]
5. Dynamic variability of hemostatic and fibrinolytic factors in young women.
Giardina EG; Chen HJ; Sciacca RR; Rabbani LE
J Clin Endocrinol Metab; 2004 Dec; 89(12):6179-84. PubMed ID: 15579775
[TBL] [Abstract][Full Text] [Related]
6. Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age.
Randolph JF; Sowers M; Bondarenko IV; Harlow SD; Luborsky JL; Little RJ
J Clin Endocrinol Metab; 2004 Apr; 89(4):1555-61. PubMed ID: 15070912
[TBL] [Abstract][Full Text] [Related]
7. Are vasomotor symptoms associated with alterations in hemostatic and inflammatory markers? Findings from the Study of Women's Health Across the Nation.
Thurston RC; El Khoudary SR; Sutton-Tyrrell K; Crandall CJ; Gold E; Sternfeld B; Selzer F; Matthews KA
Menopause; 2011 Oct; 18(10):1044-51. PubMed ID: 21926929
[TBL] [Abstract][Full Text] [Related]
8. Androgens are associated with hemostatic and inflammatory factors among women at the mid-life.
Sowers MR; Jannausch M; Randolph JF; McConnell D; Little R; Lasley B; Pasternak R; Sutton-Tyrrell K; Matthews KA
J Clin Endocrinol Metab; 2005 Nov; 90(11):6064-71. PubMed ID: 16091487
[TBL] [Abstract][Full Text] [Related]
9. Effect of pulsed estrogen therapy on hemostatic markers in comparison with oral estrogen regimen in postmenopausal women.
Basurto L; Saucedo R; Zárate A; Martínez C; Gaminio E; Reyes E; Hernandez M
Gynecol Obstet Invest; 2006; 61(2):61-4. PubMed ID: 16192735
[TBL] [Abstract][Full Text] [Related]
10. Postmenopausal oral estrogen therapy affects hemostatic factors, but does not account for reduction in the progression of subclinical atherosclerosis.
Vigen C; Hodis HN; Chandler WL; Lobo RA; Mack WJ
J Thromb Haemost; 2007 Jun; 5(6):1201-8. PubMed ID: 17389005
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory/hemostatic biomarkers and coronary artery calcification in midlife women of African-American and White race/ethnicity: the Study of Women's Health Across the Nation (SWAN) heart study.
Wang NC; Matthews KA; Barinas-Mitchell EJ; Chang CC; El Khoudary SR
Menopause; 2016 Jun; 23(6):653-61. PubMed ID: 27023861
[TBL] [Abstract][Full Text] [Related]
12. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
[TBL] [Abstract][Full Text] [Related]
13. Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN.
Sowers MR; Greendale GA; Bondarenko I; Finkelstein JS; Cauley JA; Neer RM; Ettinger B
Osteoporos Int; 2003 May; 14(3):191-7. PubMed ID: 12730778
[TBL] [Abstract][Full Text] [Related]
14. Prospective associations between inflammatory and hemostatic markers and physical functioning limitations in mid-life women: Longitudinal results of the Study of Women's Health Across the Nation (SWAN).
McClure CK; El Khoudary SR; Karvonen-Gutierrez CA; Ylitalo KR; Tomey K; VoPham T; Sternfeld B; Cauley JA; Harlow S
Exp Gerontol; 2014 Jan; 49():19-25. PubMed ID: 24212137
[TBL] [Abstract][Full Text] [Related]
15. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study.
Gebara OC; Mittleman MA; Sutherland P; Lipinska I; Matheney T; Xu P; Welty FK; Wilson PW; Levy D; Muller JE
Circulation; 1995 Apr; 91(7):1952-8. PubMed ID: 7895352
[TBL] [Abstract][Full Text] [Related]
16. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
Stephenson K; Neuenschwander PF; Kurdowska AK
Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
[TBL] [Abstract][Full Text] [Related]
17. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors.
Andersen LF; Gram J; Skouby SO; Jespersen J
Am J Obstet Gynecol; 1999 Feb; 180(2 Pt 1):283-9. PubMed ID: 9988788
[TBL] [Abstract][Full Text] [Related]
18. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.
Scarabin PY; Alhenc-Gelas M; Plu-Bureau G; Taisne P; Agher R; Aiach M
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3071-8. PubMed ID: 9409295
[TBL] [Abstract][Full Text] [Related]
19. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
[TBL] [Abstract][Full Text] [Related]
20. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O
Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
